已发表论文

人参来源的外泌体通过调节 PD-L1 减轻非小细胞肺癌的免疫逃逸

 

Authors Zhu LJ , Chen XQ, Lin QY, Feng JN, Yuan SF

Received 14 May 2025

Accepted for publication 20 June 2025

Published 24 July 2025 Volume 2025:17 Pages 1503—1512

DOI https://doi.org/10.2147/CMAR.S540462

Checked for plagiarism Yes

Review by Single anonymous peer review

Peer reviewer comments 5

Editor who approved publication: Professor Yong Teng

Lin-Jia Zhu,1 Xiao-Qiang Chen,2 Qiu-Yan Lin,2 Jie-Ni Feng,2 Shao-Fei Yuan2 

1Department of Respiratory Medicine, The Third Affiliated Hospital of Wenzhou Medical University, Ruian, Zhejiang, 325200, People’s Republic of China; 2Department of Medical Oncology, The Third Affiliated Hospital of Wenzhou Medical University; Liji Medical Research Academy; Life and Health Research Academy of Wenzhou Medical University, Ruian, Zhejiang, 325200, People’s Republic of China

Correspondence: Lin-Jia Zhu, Email jg3433@126.com

Background: Non-small cell lung cancer (NSCLC) is a major cause of cancer-related death worldwide. While PD-1/PD-L1 immune checkpoint blockade has shown promise, its efficacy is often limited by tumor-induced immune evasion. Ginseng-derived exosomes (G-Exos), as natural plant-based nanocarriers, may offer a novel strategy for immunomodulation. This study investigated the potential of G-Exos to regulate PD-L1 expression and enhance anti-tumor immunity in NSCLC.
Methods: Exosomes were isolated from ginseng cell cultures and characterized via transmission electron microscopy and nanoparticle tracking analysis. Uptake by NSCLC cells was confirmed using PKH26 labeling. In vitro, NSCLC cells were co-cultured with activated T cells to evaluate cytotoxicity (colony formation), cytokine secretion [enzyme-linked immunosorbent assay (ELISA)], and T-cell activation (flow cytometry). PD-L1 expression was assessed by quantitative polymerase chain reaction (qPCR) and Western blot. In vivo, C57BL/6 mice (n = 20) bearing Lewis lung carcinoma (LLC) tumors were randomized into four groups (n = 5/group): PBS, G-Exos (10 μg), anti-PD-L1 (8 μg), or combination therapy. Treatments were administered intravenously every other day for 20 days. Tumor growth was measured, and tissues were analyzed by immunohistochemistry and flow cytometry.
Results: G-Exos were efficiently internalized by NSCLC cells and demonstrated immunostimulatory properties in vitro. They enhanced T-cell-mediated cytotoxicity, as reflected by reduced tumor colony formation, and promoted immune activation, evidenced by increased IL-2 and IFN-γ secretion and a higher proportion of CD8 T cells expressing TNF-α and perforin. Mechanistically, G-Exos downregulated PD-L1 expression at both transcriptional and translational levels in NSCLC cells. In vivo, G-Exos treatment significantly inhibited tumor growth and, when combined with anti-PD-L1 monoclonal antibody, exhibited a synergistic effect characterized by greater tumor suppression and increased infiltration of cytotoxic CD8 T cells in the tumor microenvironment.
Conclusion: Ginseng-derived exosomes downregulate PD-L1 and enhance T-cell function, counteracting immune evasion in NSCLC. Their synergy with anti-PD-L1 therapy supports their potential as adjuvant nanotherapeutics in cancer immunotherapy.

Keywords: non-small cell lung cancer (NSCLC), PD-1/PD-L1 axis, ginseng-derived exosomes, immune checkpoints